Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Pharma Pipeline Stalls for First Time in Decades: Citeline
  • Pipeline

Pharma Pipeline Stalls for First Time in Decades: Citeline

BioSpace

Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.

PipelineRead full story

pharminent April 6, 2026 (Last updated: April 6, 2026)

BioSpace

Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.

PipelineRead full story

Post navigation

Previous: The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
Next: Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal

Related Stories

  • Pipeline

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

pharminent August 11, 2026
  • Pipeline

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

pharminent August 11, 2026
  • Pipeline

BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication

pharminent August 10, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.